-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98

Benzinga·08/19/2026 09:53:54
Listen to the news
BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.